1
00:00:00,080 --> 00:00:03,040
Speaker 1: Maternal out already reporting a narrow with an expected first

2
00:00:03,080 --> 00:00:06,240
Speaker 1: quarter loss cost cutting of setting a steep decline in

3
00:00:06,280 --> 00:00:09,480
Speaker 1: its COVID business. Maternal expecting to receive US approval for

4
00:00:09,560 --> 00:00:12,959
Speaker 1: its second product, an RSV vaccine, in the coming days,

5
00:00:13,039 --> 00:00:15,880
Speaker 1: joining us now as the Maternal CEO. Stephan Bansal, Stephan,

6
00:00:15,920 --> 00:00:17,840
Speaker 1: wonderful to catch up with you, sir. The stock is

7
00:00:17,920 --> 00:00:20,120
Speaker 1: just about positive in the pre market. Can you talk

8
00:00:20,120 --> 00:00:23,280
Speaker 1: to me about how you're balancing cost cutting with investing

9
00:00:23,280 --> 00:00:25,680
Speaker 1: in innovation given what's in the pipeline.

10
00:00:26,600 --> 00:00:29,040
Speaker 2: Sure, well, good morning, Thank you for having me so

11
00:00:29,280 --> 00:00:32,519
Speaker 2: very pleased with a quote. We basically try to focus

12
00:00:32,760 --> 00:00:35,199
Speaker 2: on how do we drive sales, how do we drive

13
00:00:35,360 --> 00:00:38,040
Speaker 2: R and D, how do we prioritize opportunities, which is

14
00:00:38,080 --> 00:00:40,760
Speaker 2: the way. For example, we announced that we are stopping

15
00:00:40,800 --> 00:00:44,519
Speaker 2: the partnership with Metagenom in research engine editing.

16
00:00:44,960 --> 00:00:45,760
Speaker 3: Same thing if you look.

17
00:00:45,640 --> 00:00:48,879
Speaker 2: At the portfolio, we're looking very carefully at all investments.

18
00:00:49,360 --> 00:00:53,400
Speaker 2: And the good thing about those vaccines, like respiratory vaccines

19
00:00:53,479 --> 00:00:56,280
Speaker 2: is your only pay the face free study. Whats so

20
00:00:56,280 --> 00:00:58,600
Speaker 2: if you think about COVID, we still up sells from COVID,

21
00:00:59,040 --> 00:01:01,279
Speaker 2: but the investment in the idea of COVID has come

22
00:01:01,320 --> 00:01:04,040
Speaker 2: down a lot. As you said ours, we we are

23
00:01:04,080 --> 00:01:07,360
Speaker 2: anticipating a launch this spring, but we're not going to

24
00:01:07,400 --> 00:01:09,520
Speaker 2: do another Phase three four URSV, so you can still

25
00:01:09,720 --> 00:01:13,520
Speaker 2: basically have a lot of new studies going on. We're

26
00:01:13,600 --> 00:01:15,760
Speaker 2: using the capital you used to put in the other

27
00:01:15,880 --> 00:01:18,679
Speaker 2: products before. And then if you look at oncology, as

28
00:01:18,720 --> 00:01:20,720
Speaker 2: you know, we're in a fifty to fifty profit share

29
00:01:20,760 --> 00:01:23,200
Speaker 2: with Merk, so merk is paying half of a phase

30
00:01:23,280 --> 00:01:25,640
Speaker 2: free study. So that's how we're managing when we're seeing

31
00:01:25,640 --> 00:01:28,600
Speaker 2: a lot in technology. You might have seen last week

32
00:01:28,880 --> 00:01:32,000
Speaker 2: an announcement with open Ai. We actually more than seven

33
00:01:32,040 --> 00:01:34,800
Speaker 2: hundred fifty GPT is going and that is helping us

34
00:01:34,840 --> 00:01:37,800
Speaker 2: a lot scale the company across not only science but

35
00:01:37,920 --> 00:01:41,480
Speaker 2: surd having a lot of productivity in manufacturing in commercial

36
00:01:41,600 --> 00:01:43,680
Speaker 2: illegal So that's kind of how we're doing it.

37
00:01:43,920 --> 00:01:45,840
Speaker 1: So Stephan, let's talk about something that our colleagues here

38
00:01:45,880 --> 00:01:49,240
Speaker 1: at Bloomberger extremely focused on, and that's your RS three shot,

39
00:01:49,640 --> 00:01:52,080
Speaker 1: which according to our colleagues, some data is showing that

40
00:01:52,160 --> 00:01:54,600
Speaker 1: maybe it doesn't last as long as others in the market.

41
00:01:54,760 --> 00:01:56,320
Speaker 1: What we all want to know here at Bloomberger is

42
00:01:56,320 --> 00:01:59,200
Speaker 1: whether that raises questions about the promise of your technology

43
00:01:59,240 --> 00:02:01,760
Speaker 1: in treating other diseases. How would you answer that?

44
00:02:03,160 --> 00:02:04,800
Speaker 2: So will first say that if you look at the

45
00:02:04,920 --> 00:02:08,240
Speaker 2: data the duration of the over vaccines, they are very similar.

46
00:02:08,480 --> 00:02:11,519
Speaker 2: So I don't think it is scientifically correct to say

47
00:02:11,520 --> 00:02:13,960
Speaker 2: that one of a vaccine doesn't last as long as

48
00:02:14,000 --> 00:02:17,480
Speaker 2: your ones of a too that are improved and ours.

49
00:02:17,760 --> 00:02:20,720
Speaker 2: Look at the data. This will be debated at the

50
00:02:20,760 --> 00:02:24,840
Speaker 2: CDC meeting at the end of drewne that for reccommodations.

51
00:02:25,520 --> 00:02:27,960
Speaker 2: So this doesn't worry me. If you look at duration,

52
00:02:28,639 --> 00:02:32,680
Speaker 2: the duration of vaccination is induced by T cell. If

53
00:02:32,720 --> 00:02:35,919
Speaker 2: you look at cancer product, the only reason it works

54
00:02:36,400 --> 00:02:39,240
Speaker 2: is T cells, not antibodies. Antibodies don't have a row

55
00:02:39,360 --> 00:02:42,960
Speaker 2: in cancer. It's about T cells going and attacking your cancer.

56
00:02:43,440 --> 00:02:46,519
Speaker 2: If our vaccine technology didn't have good T cell response,

57
00:02:46,919 --> 00:02:49,040
Speaker 2: the cancer product will not look as good as it is.

58
00:02:49,400 --> 00:02:51,520
Speaker 2: So I'm not worried at all about duration.

59
00:02:52,280 --> 00:02:54,960
Speaker 4: Pretty much every time we speak, Stefan, I ask you, basically,

60
00:02:54,960 --> 00:02:56,640
Speaker 4: have we couraged cancer yet? So I'm glad that you

61
00:02:56,680 --> 00:02:58,400
Speaker 4: went there because that's been sort of one of the

62
00:02:58,400 --> 00:03:01,120
Speaker 4: big questions in the hope for a lot of the

63
00:03:01,240 --> 00:03:04,680
Speaker 4: MR and A vaccines. You have this Melanima vaccine in

64
00:03:04,720 --> 00:03:06,760
Speaker 4: the works, what more do you have to do to

65
00:03:06,800 --> 00:03:09,640
Speaker 4: get it sort of set up for the approval process

66
00:03:09,680 --> 00:03:12,720
Speaker 4: to apply for that and are you using artificial intelligence

67
00:03:12,720 --> 00:03:13,800
Speaker 4: to extradite.

68
00:03:13,360 --> 00:03:15,320
Speaker 3: That great question.

69
00:03:15,639 --> 00:03:19,680
Speaker 2: So if you look at cancer treatment in melanoma, we've

70
00:03:19,720 --> 00:03:23,080
Speaker 2: said that we need to achieve free things to be

71
00:03:23,160 --> 00:03:27,400
Speaker 2: able to talk to regulator about accelerated approval. So the

72
00:03:27,440 --> 00:03:29,720
Speaker 2: face to day ties data we shared on the show

73
00:03:30,080 --> 00:03:34,240
Speaker 2: several times, we see duration. If you remember in December

74
00:03:34,240 --> 00:03:37,000
Speaker 2: we shad a three year survival. It was better than

75
00:03:37,040 --> 00:03:39,720
Speaker 2: the two year survival. So the difference between people on

76
00:03:39,840 --> 00:03:43,560
Speaker 2: all treatment and people that are just getting cathedral is

77
00:03:43,560 --> 00:03:47,360
Speaker 2: getting wider. So there's a very strong evidence that the

78
00:03:47,440 --> 00:03:48,360
Speaker 2: drug is working.

79
00:03:48,400 --> 00:03:49,320
Speaker 3: So that's number one.

80
00:03:49,760 --> 00:03:53,280
Speaker 2: Number two is we need a phase free study to

81
00:03:53,400 --> 00:03:57,560
Speaker 2: be substantially enrolled, and so we are working very actively.

82
00:03:57,920 --> 00:04:01,600
Speaker 2: Face free study started two months earlier plan last summer

83
00:04:02,200 --> 00:04:05,120
Speaker 2: and so when we are substantially enrolled, we will meet

84
00:04:05,120 --> 00:04:08,280
Speaker 2: that criteria and it could be late this year. And

85
00:04:08,320 --> 00:04:10,800
Speaker 2: the third one is a plant because of course we

86
00:04:10,880 --> 00:04:14,560
Speaker 2: need to file in the restrection du all the information

87
00:04:14,640 --> 00:04:19,000
Speaker 2: about the manufacturing process BFD the day you file is

88
00:04:19,080 --> 00:04:22,159
Speaker 2: allowed to go, of course, audit your plant. That plant

89
00:04:22,200 --> 00:04:23,720
Speaker 2: is being built. I had a chance to go there

90
00:04:23,760 --> 00:04:27,160
Speaker 2: two weeks ago. The team is working NonStop, scheduling literally

91
00:04:27,160 --> 00:04:29,479
Speaker 2: by the days, a bit like we did during COVID

92
00:04:29,560 --> 00:04:34,120
Speaker 2: during the pandemic, and so I anticipate that potentially sometime

93
00:04:34,200 --> 00:04:37,520
Speaker 2: next year, you know, the if a regulator was willing

94
00:04:37,560 --> 00:04:40,839
Speaker 2: to look at the accelerated approval file, we should have

95
00:04:40,880 --> 00:04:42,960
Speaker 2: this product available to help a lot of people, because

96
00:04:43,040 --> 00:04:46,440
Speaker 2: one in two people benefit with no thises coming back

97
00:04:46,600 --> 00:04:49,560
Speaker 2: or our deaths compared to the best drug available today

98
00:04:49,560 --> 00:04:50,480
Speaker 2: to them on the market.

99
00:04:50,680 --> 00:04:52,479
Speaker 4: Stephan, can you just give us a sense of you

100
00:04:52,520 --> 00:04:56,120
Speaker 4: talk about artificial intelligence. Everyone's talking about artificial intelligence. Could

101
00:04:56,120 --> 00:04:58,720
Speaker 4: you just talk about how much that could expedite generally

102
00:04:59,160 --> 00:05:01,640
Speaker 4: some of the drug production that we're seeing. Just how

103
00:05:01,760 --> 00:05:05,039
Speaker 4: much that could really get us to achieve you know,

104
00:05:05,080 --> 00:05:09,200
Speaker 4: that cure for cancer, that cure for als, cure for Alzheimer's.

105
00:05:09,400 --> 00:05:11,160
Speaker 4: You know, it's funny you're talking about sex and city.

106
00:05:11,200 --> 00:05:12,720
Speaker 4: I sit around and I worry about these things. You know,

107
00:05:12,760 --> 00:05:14,880
Speaker 4: what are we to cure these things? So I'm just wondering,

108
00:05:14,920 --> 00:05:17,200
Speaker 4: you know, this is going to be in our lifetime

109
00:05:17,200 --> 00:05:19,600
Speaker 4: in the next couple of years because of some of

110
00:05:19,600 --> 00:05:20,960
Speaker 4: the machine learning.

111
00:05:22,320 --> 00:05:24,360
Speaker 2: Yes, so I think there's a few things to tear

112
00:05:24,400 --> 00:05:27,279
Speaker 2: part in your in your great question. First is I

113
00:05:27,320 --> 00:05:31,760
Speaker 2: think machine learning in academic labs, in research labs, in

114
00:05:31,760 --> 00:05:36,360
Speaker 2: industry is helping accelerate the understanding of a human body.

115
00:05:36,880 --> 00:05:39,440
Speaker 2: If you think about you know, this is Alzheimer and

116
00:05:39,480 --> 00:05:42,320
Speaker 2: all those complicated disease that we do not have solutions

117
00:05:42,320 --> 00:05:46,000
Speaker 2: for yet as a society. It's because we do not

118
00:05:46,240 --> 00:05:49,920
Speaker 2: understand the biology. We do not understand how the disease happened,

119
00:05:50,000 --> 00:05:52,599
Speaker 2: how the disease evolved, and so we are just trying

120
00:05:52,680 --> 00:05:56,960
Speaker 2: things and some work, but very few work. Most of

121
00:05:56,960 --> 00:05:59,680
Speaker 2: them don't work because we're just trying and guessing. If

122
00:05:59,680 --> 00:06:02,240
Speaker 2: you look at a biology, once we understand that something works,

123
00:06:02,560 --> 00:06:06,240
Speaker 2: then the industry can comes with very very good actions

124
00:06:06,520 --> 00:06:08,520
Speaker 2: to deal with those. So I think AI will accelerate

125
00:06:08,600 --> 00:06:11,479
Speaker 2: the understanding of biology, which would be fundamental to bring

126
00:06:11,520 --> 00:06:15,320
Speaker 2: new drug. Then AI is already used to accelerate discovery

127
00:06:15,400 --> 00:06:17,320
Speaker 2: in terms of what tool do you go after a

128
00:06:17,360 --> 00:06:20,719
Speaker 2: disease once you understand it. At modern already we have

129
00:06:20,839 --> 00:06:24,320
Speaker 2: different chemical matters that are generated by our AI system

130
00:06:24,640 --> 00:06:27,400
Speaker 2: that are helping us to accelerate the work that humans

131
00:06:27,440 --> 00:06:29,839
Speaker 2: are doing. So it's an accelerator to the teams. And

132
00:06:29,880 --> 00:06:33,160
Speaker 2: then there's a huge chapter on productivity. If you think

133
00:06:33,200 --> 00:06:37,279
Speaker 2: about clinical development phase one, two and three, it's basically

134
00:06:37,320 --> 00:06:41,960
Speaker 2: doing experiment in human, getting the data, finding the doors,

135
00:06:42,520 --> 00:06:45,560
Speaker 2: doing more experiment, and when you have all studied on,

136
00:06:45,720 --> 00:06:48,120
Speaker 2: you get all the data and you submit by relator.

137
00:06:48,520 --> 00:06:49,960
Speaker 3: My point is it's all about data.

138
00:06:50,000 --> 00:06:53,520
Speaker 2: They are literally hundreds of business processes that need to happen,

139
00:06:53,880 --> 00:06:56,760
Speaker 2: and I think many of those, if not most of those,

140
00:06:56,839 --> 00:06:59,280
Speaker 2: you've got to be able to apply AI to shrink

141
00:06:59,520 --> 00:07:03,160
Speaker 2: time to go faster. An example we shared in March

142
00:07:03,240 --> 00:07:06,839
Speaker 2: in a vaccine. Then the team wrote a GPT to

143
00:07:06,880 --> 00:07:09,440
Speaker 2: help us to do those selections. When you do clinical

144
00:07:09,480 --> 00:07:12,720
Speaker 2: study your phase one, you try several doses and then

145
00:07:12,720 --> 00:07:14,560
Speaker 2: based on the data you get in a clinic, you

146
00:07:14,640 --> 00:07:17,840
Speaker 2: decide which jos go into your phase three. Well, it

147
00:07:18,000 --> 00:07:20,320
Speaker 2: used to take around a month to do that by

148
00:07:20,360 --> 00:07:23,200
Speaker 2: having people and meeting and experts looking at the data

149
00:07:23,360 --> 00:07:26,880
Speaker 2: while we develop a GPT that basically get all the

150
00:07:26,960 --> 00:07:30,680
Speaker 2: data from the clinical study and suggests to us a

151
00:07:30,760 --> 00:07:33,720
Speaker 2: those in literally a minutes or two. That is already

152
00:07:33,880 --> 00:07:36,720
Speaker 2: a tool that has been developed that I've seen used

153
00:07:36,760 --> 00:07:37,440
Speaker 2: at the company.

154
00:07:37,680 --> 00:07:39,559
Speaker 3: That's just one example. So here you go to shrink

155
00:07:39,560 --> 00:07:39,920
Speaker 3: them off.

156
00:07:40,160 --> 00:07:42,120
Speaker 2: And if you do that on the hundreds of business

157
00:07:42,200 --> 00:07:44,880
Speaker 2: processes that have to happen in preparing the drug for

158
00:07:44,920 --> 00:07:48,280
Speaker 2: the clinic, the clinical testing, the analyzing of the data,

159
00:07:48,640 --> 00:07:51,360
Speaker 2: the communication with the FDA, I think you can save

160
00:07:51,440 --> 00:07:53,800
Speaker 2: a lot of time. I don't know yet, because only

161
00:07:53,920 --> 00:07:56,160
Speaker 2: history will show us in the next few years, can

162
00:07:56,200 --> 00:07:58,920
Speaker 2: you shave thirty percent, forty percent, fifty percent of how

163
00:07:58,920 --> 00:08:01,239
Speaker 2: many years it takes you to develop a drug?

164
00:08:01,280 --> 00:08:02,800
Speaker 3: I think it's going to be very significant.

165
00:08:03,800 --> 00:08:05,600
Speaker 1: Stephan, We've got to leave you there. It's fantastic to

166
00:08:05,640 --> 00:08:07,640
Speaker 1: catch up with you, so amazing to listen to you

167
00:08:07,800 --> 00:08:10,640
Speaker 1: talk about the efforts taking place at Maderna. Madenna CEO

168
00:08:10,680 --> 00:08:11,520
Speaker 1: Stefan Bansell